Inhibition of WEE1 promotes the immune response via the STING-TBK1-IRF3 pathway, enhances the antitumor effect of PD-L1 antibodies through the STAT1 pathway, and significantly suppresses tumor progression in SCLC models (including MYC-stabilized SCLC) [150]. The gene discussed is WEE1; the disease is neoplasm.